Genomic Interrogation of Secondary-Type Acute Myeloid Leukemia: Response and Outcomes to Contemporary Therapies,” published in the February 2025 issue of American Journal of Hematology by Senapati et ...

Researchers at the LKS Faculty of Medicine of the University of Hong Kong (HKUMed) have invented an oral formulation of ...

In January 2025, Aptose announced the initiation of the TUSCANY trial and dosing in the first cohort of newly-diagnosed AML patients with the lowest starting dose (40 mg) of TUS as part of the ...

HOUSTON - Moleculin Biotech, Inc. (NASDAQ:MBRX), a late-stage pharmaceutical company currently trading near its 52-week low of $0.66, announced it has received the first European regulatory approval ...

Background: Human monocytic ehrlichiosis (HME) is a tick-borne illness caused by Ehrlichia chaffeensis. Data about disease in children have been largely derived from case reports or small case series.

Acute lymphocytic leukaemia (ALL) is a cancer of the blood and bone marrow, specifically affecting lymphocytes. The disease progresses rapidly and creates immature blood cells, rather than mature ...

Acquired miR-142 deficit in leukemic stem cells has been associated with chronic myeloid leukemia blast crisis. Here the authors show that acquired miR-142 deficit in T cells further enables ...

ALA = Amoebic liver abscess; Eh = Entamoeba histolytica; EhCP = E. histolytica cysteine proteinase; Ehserp = E. histolytica serine proteinase; EhSTIRP = Serine threonine isoleucine-rich protein ...

US-based pharmaceutical company Moleculin Biotech has received approval from Ukraine's Ministry of Health to begin enrolment in its Phase III trial of annamycin with cytarabine for treating acute ...